ZNTL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
31.2M
-29.8%
44.4M
+17.3%
37.9M
+1.2%
37.4M
+10.8%
33.7M
R&D
22.3M
-36.5%
35.2M
+22.5%
28.7M
-2.6%
29.5M
+28.5%
22.9M
SG&A
8.8M
-4.4%
9.2M
+1.0%
9.1M
+15.6%
7.9M
-26.7%
10.8M
Operating Income
-31154000
+29.8%
-44391000
-17.3%
-37855000
-1.2%
-37393000
-10.8%
-33734000
EBITDA
-31002000
+29.9%
-44238000
-17.3%
-37704000
-1.3%
-37236000
-10.9%
-33574000
Net Income
-28815000
+31.9%
-42286000
-19.6%
-35352000
-0.4%
-35216000
-31.9%
-26691000
EPS (Basic)
$-0.34
+42.4%
$-0.59
-18.0%
$-0.50
-2.0%
$-0.49
-32.4%
$-0.37
EPS (Diluted)
$-0.34
+42.4%
$-0.59
-18.0%
$-0.50
-2.0%
$-0.49
-32.4%
$-0.37
Shares (Diluted)
84.6M
+18.6%
71.3M
+1.5%
70.3M
-2.0%
71.7M
-0.7%
72.1M
Zentalis Pharmaceuticals (ZNTL) — Financials